Amgen, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1980-01-01
- Employees
- 26.7K
- Market Cap
- $175.6B
- Website
- http://www.amgen.com
A Study to Evaluate the Effect of CCX140-B on Urinary Albumin Excretion in Subjects With Type 2 Diabetes and Albuminuria
Phase 2
Completed
- Conditions
- Diabetic NephropathyType 2 Diabetes Mellitus
- Interventions
- Drug: PlaceboDrug: CCX140-B
- First Posted Date
- 2011-09-26
- Last Posted Date
- 2025-02-27
- Lead Sponsor
- Amgen
- Target Recruit Count
- 20
- Registration Number
- NCT01440257
- Locations
- 🇳🇱
Centre for Human Drug Research, Leiden, Netherlands
Safety & Tolerability of Cinacalcet in Pediatric Patients With Chronic Kidney Disease and Secondary Hyperparathyroidism
Phase 2
Terminated
- Conditions
- Hyperparathyroidism, SecondaryChronic Kidney Disease
- Interventions
- Drug: Standard of Care
- First Posted Date
- 2011-09-23
- Last Posted Date
- 2020-06-17
- Lead Sponsor
- Amgen
- Target Recruit Count
- 18
- Registration Number
- NCT01439867
- Locations
- 🇸🇰
Research Site, Kosice, Slovakia
Open Label Study of Long Term Evaluation Against LDL-C Trial
Phase 2
Completed
- Conditions
- Hypercholesterolemia
- Interventions
- Biological: EvolocumabOther: Standard of care
- First Posted Date
- 2011-09-23
- Last Posted Date
- 2022-09-21
- Lead Sponsor
- Amgen
- Target Recruit Count
- 1324
- Registration Number
- NCT01439880
- Locations
- 🇬🇧
Research Site, London, United Kingdom
Study to Evaluate Darbepoetin Alfa in Pediatric Subjects With Anemia Due to Chronic Kidney Disease
- First Posted Date
- 2011-09-02
- Last Posted Date
- 2016-06-17
- Lead Sponsor
- Amgen
- Registration Number
- NCT01428154
Open-Label Access Protocol of Denosumab for Subjects With Advanced Cancer
Phase 3
Completed
- Conditions
- Bone Metastases in Men With Hormone-Refractory Prostate CancerBone Metastases in Subjects With Advanced Breast Cancer
- Interventions
- First Posted Date
- 2011-08-18
- Last Posted Date
- 2019-09-24
- Lead Sponsor
- Amgen
- Target Recruit Count
- 129
- Registration Number
- NCT01419717
- Locations
- 🇺🇦
Research Site, Lviv, Ukraine
Open-label Study of the Safety and Activity of Oprozomib in Patients With Hematologic Malignancies
Phase 1
Terminated
- Conditions
- Multiple MyelomaWaldenstrom Macroglobulinemia
- Interventions
- First Posted Date
- 2011-08-15
- Last Posted Date
- 2022-11-08
- Lead Sponsor
- Amgen
- Target Recruit Count
- 210
- Registration Number
- NCT01416428
- Locations
- 🇺🇸
Mayo Clinic Scottsdale, Scottsdale, Arizona, United States
🇺🇸University of Chicago Medical Center, Chicago, Illinois, United States
🇺🇸Pacific Cancer Care, Salinas, California, United States
Comparison of Survival Benefit of Panitumumab With Supportive Care to Best Supportive Care Alone in Patients With Metastatic Colorectal Cancer
Phase 3
Completed
- Conditions
- Metastatic Colorectal Cancer
- Interventions
- Other: Best Supportive Care (BSC)
- First Posted Date
- 2011-08-09
- Last Posted Date
- 2017-03-15
- Lead Sponsor
- Amgen
- Target Recruit Count
- 377
- Registration Number
- NCT01412957
- Locations
- 🇷🇸
Research Site, Sremska Kamenica, Serbia
Carfilzomib Multiple Myeloma Expanded Access Protocol for Patients With Relapsed and Refractory Disease
- Conditions
- Multiple Myeloma
- First Posted Date
- 2011-08-05
- Last Posted Date
- 2017-05-02
- Lead Sponsor
- Amgen
- Registration Number
- NCT01410500
Double-blind, Multiple Dose Study of Tezepelumab (AMG 157) in Adults With Mild Atopic Asthma
Phase 1
Completed
- Conditions
- Asthma
- Interventions
- Drug: PlaceboBiological: Tezepelumab
- First Posted Date
- 2011-07-29
- Last Posted Date
- 2022-10-17
- Lead Sponsor
- Amgen
- Target Recruit Count
- 31
- Registration Number
- NCT01405963
- Locations
- 🇨🇦
Research Site, Saskatoon, Saskatchewan, Canada
Safety, Tolerability, and Pharmacokinetics of AMG 827 in Adolescents With Asthma
Phase 1
Withdrawn
- Conditions
- Asthma
- Interventions
- Drug: AMG 827 or Placebo
- First Posted Date
- 2011-07-15
- Last Posted Date
- 2013-11-25
- Lead Sponsor
- Amgen
- Registration Number
- NCT01395485
© Copyright 2025. All Rights Reserved by MedPath